期刊
EUROPEAN HEART JOURNAL
卷 33, 期 2, 页码 165-U148出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehr239
关键词
Pharmacogenetics; Single-nucleotide polymorphism; Drug therapy; Drug response; Cardiovascular disease; Systematic review
资金
- European Union [HEALTH-F2-2009-223004]
- Interuniversity Cardiology Institute of the Netherlands (ICIN)
- Durrer Center for Cardiogenetic Research both Institutes of the Netherlands Royal Academy of Arts and Sciences (KNAW)
- Netherlands Heart Foundation [2001D032]
- Center for Medical Systems Biology (CMSB)
- centre of excellence approved by the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NWO)
- Netherlands Consortium for Healthy Ageing (NCHA)
Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the greatest potential of efficacy and smallest risk of adverse drug reactions. Many studies focusing on drug-gene interactions have been published in recent years, some of which led to adaptation of FDA recommendations, indicating that we are on the verge of the clinical application of genetic information in drug therapy. This systematic review provides a comprehensive overview of the current knowledge on pharmacogenetics of all major drug classes currently used in the treatment of cardiovascular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据